In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and look for ways to adapt. The following statements detail the point of view of Vatche Bartekian, President of Vantage BioTrials Inc.
In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and look for ways to adapt. The following statements detail the point of view of Marc Rivière, Chief Medical Officer, TVM Capital and Chairman of the Board of Directors, CATALIS Québec.
The Quebec Government’s 2020–2021 budget, tabled yesterday by Minister of Finance Éric Girard, mentions investments in the field of clinical research, a commitment that was favourably received by CATALIS Québec’s board of directors.
Quebec is a top destination for life sciences and clinical research. To strengthen our efforts to spread this message beyond Quebec, CATALIS Québec has joined The Coolest Hotspot network.
A team from the CHU de Québec-Université Laval has begun a clinical trial in order to develop new therapeutic options for the treatment of pancreatic adenocarcinoma, an aggressive cancer whose survival rate is less than one year.
2020 promises to be a pivotal year for the rise of clinical research in Quebec. With our partners and sector stakeholders, we are taking concrete steps towards making Quebec an authority in the clinical trial sector.
The CHU de Québec-Université Laval (CRCHU) Research Centre has worked extra hard this year to stimulate launches of early-stage clinical research projects in the Quebec City region. The Research Centre is about to double the number of clinical trials conducted in its institutions.
CATALIS Québec launches a promotional campaign to demonstrate Quebec’s expertise in the conduct of early-phase clinical trials and to encourage new partnerships between the biopharmaceutical industry and university research centres.
Clinical trials, cell therapies and partnerships with different specialities: the hematology/oncology research team at the Hôpital de l’Enfant-Jésus (HEJ) in Quebec City is involved in all areas where research can make a difference for its patients.
On August 29th, the management team at the CHUM Research Centre officially opened its Unit for Innovative Therapies (UIT), a competitive infrastructure for early-stage clinical research in Canada.